Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.49 USD | +2.32% | +2.28% | +16.90% |
Mar. 14 | Barrington Ups Price Target on Anika Therapeutics to $37 From $29, Keeps Outperform Rating | MT |
Mar. 13 | Transcript : Anika Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.90% | 388M | |
-3.77% | 86.16B | |
+2.76% | 40.17B | |
-16.48% | 31.47B | |
+57.86% | 25.24B | |
-13.58% | 15.82B | |
-9.12% | 11.96B | |
-42.56% | 11.61B | |
+6.89% | 8.84B | |
-6.20% | 7.93B |
- Stock Market
- Equities
- ANIK Stock
- News Anika Therapeutics, Inc.
- Barrington Research Downgrades Anika Therapeutics to Market Perform From Outperform